MONROVIA, Calif., Oct. 3,
2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a
clinical-stage biopharmaceutical company developing engineered
monoclonal antibodies for the treatment of autoimmune diseases,
asthma and allergic diseases and cancer, today announced that
preliminary data from an ongoing open-label Phase 2 study of
XmAb®5871 in patients with IgG4-Related Disease will be
presented during an oral presentation on Sunday, November 13 at the American College of
Rheumatology (ACR) 2016 Annual Meeting. An abstract of the
presentation is available on the ACR conference website at:
http://acrabstracts.org/. Information contained in the abstract was
at the time of submission in June
2016. An updated data set will be presented at the ACR
Annual Meeting in November.
Abstract: 940
Title: A Trial of XmAb®5871, a Reversible
Inhibitor of CD19+ Cells, in IgG4-Related Disease
Presenter: John H. Stone,
Massachusetts General Hospital Rheumatology Unit, Harvard Medical School
Session: Miscellaneous Rheumatic and Inflammatory
Diseases - Oral Session I
Session date and time: Sunday,
November 13, 2016 2:30-4:00 p.m.
ET
XmAb®5871
XmAb®5871
is a first-in-class monoclonal antibody that targets CD19 with its
variable domain and that uses Xencor's XmAb immune
inhibitor Fc domain to target FcγRIIb, a receptor that inhibits
B-cell function. XmAb5871 is the first drug candidate
that Xencor is aware of that targets FcγRIIb
inhibition. Xencor has demonstrated in multiple animal
models and in initial human clinical trials that XmAb5871 inhibits
B-cell function without destroying these important immune cells,
and demonstrated promising treatment effect in patients with
rheumatoid arthritis, as well as ex vivo results showing inhibition
of SLE patient B-cell activation and humoral immunity.
About IgG4-Related Disease
IgG4-Related Disease
(IgG4-RD) is a rare fibro-inflammatory autoimmune disorder that we
estimate impacts up to 40,000 patients in the United States. IgG4-RD affects multiple organ
systems and is characterized by a distinct microscopic appearance
of diseased organs, including the presence of IgG4-positive
plasmablast cells. This objective diagnostic criterion is atypical
for autoimmune diseases and offers advantages for accurately
identifying patients. There are currently no approved therapies for
this newly recognized disorder and corticosteroids are the current
standard of care. John H. Stone, M.D, MPH, director, clinical
rheumatology at Massachusetts General Hospital has developed
and is validating the IgG4-RD Responder Index, a proposed
instrument to assess disease activity.
About Xencor's XmAb® Immune Inhibitor Technology
FcγRIIb (IIb), also called CD32b, is a receptor for Fc domains on B
cells and other immune cells. When engaged, the IIb receptor blocks
immune activation pathways and traffics bound soluble antigens out
of circulation. Xencor has discovered a series of Fc domain
variants with up to a 400-fold increase in binding affinity to
FcγRIIb derived from just two amino acid changes. These XmAb®
Immune Inhibitor Fc domains greatly heighten the properties of IIb
receptor engagement and have potential as building blocks for drug
candidates in autoimmune, allergic and inflammatory diseases.
About Xencor, Inc.
Xencor is a clinical-stage
biopharmaceutical company developing engineered monoclonal
antibodies for the treatment of autoimmune diseases, asthma and
allergic diseases and cancer. Currently, 10 candidates engineered
with Xencor's XmAb® technology are in clinical development
internally and with partners. Xencor's internal programs include:
XmAb5871 in Phase 2 development for the treatment of IgG4-Related
Disease, and also for the treatment of Systemic Lupus
Erythematosus; XmAb7195 in Phase 1 development for the treatment of
asthma and allergic diseases; XmAb14045 in Phase 1 development for
acute myeloid leukemia; and XmAb13676 for B-cell malignancies and
XmAb18087 for the treatment of neuroendocrine tumors, both in
pre-clinical development. Xencor's XmAb antibody engineering
technology enables small changes to the structure of monoclonal
antibodies resulting in new mechanisms of therapeutic action.
Xencor partners include Novartis, Amgen, MorphoSys, Merck,
CSL/Janssen, Alexion, Novo Nordisk and Boehringer Ingelheim. For
more information, please visit www.xencor.com.
Forward Looking Statements:
Statements contained in
this press release regarding matters that are not historical facts
are forward-looking statements within the meaning of applicable
securities laws and any expectations relating to its business,
research and development programs, including ongoing clinical
trials of XmAb5871, and the immune inhibitory Fc domain technology,
partnering efforts or its capital requirements. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements,
including those of the complete clinical trial of XmAb5871, and the
timing of events to be materially different from those implied by
such statements, and therefore these statements should not be read
as guarantees of future performance or results. Such risks include,
without limitation, the risks associated with the process of
discovering, developing, manufacturing and commercializing drugs
that are safe and effective for use as human therapeutics and other
risks described in Xencor's public securities filings.
All forward-looking statements are based
on Xencor's current information and belief as well as
assumptions made by Xencor. Readers are cautioned not to place
undue reliance on such statements and Xencor disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/preliminary-data-from-the-ongoing-open-label-xmab5871-phase-2-pilot-study-in-igg4-related-disease-to-be-presented-at-american-college-of-rheumatology-acr-2016-annual-meeting-300337797.html
SOURCE Xencor, Inc.